iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 prescription trends through June Novo said its research shows

It is provided solely for laboratory research purposes and must not be used for diagnostic or therapeutic purposes, in food, cosmetics, or any medical applications

Cardiometabolic Markers: Both drugs dramatically improve key indicators

Case reports, conference abstracts, nonpeer-reviewed sources, and studies lacking clear outcome measures were excluded

Impact on body weight: GLP-1 receptor activation tends to promote weight loss, while GIP receptor activation may promote weight gain through its effects on fat storage

Therefore, we hypothesized that semaglutide could reduce the risk of Alzheimers disease by targeting directly or indirectly these modifiable risk factors, neurodegeneration and neuroinflammation, Xu added